← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #486 OF 1,000 MOST-CITED

Complete instructions, procedures, specifications et. al.

FDA cited this observation 39 times across 38 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs39
BY FISCAL YEAR
FY20252
FY20243
FY20235
FY20224
FY20211
FY20205
FY201910
FY20188
FY20171

How FDA worded it — real examples

Master production and control records lack complete manufacturing and control instructions.

GI Accelerate Memphis LLC · Memphis, Tennessee · Drugs · 2025-02-07

Master production and control records lack complete manufacturing and control instructions and sampling and testing procedures.

Shilpa Medicare Limited · Dabaspet, Bengaluru · Drugs · 2024-10-30

Master production and control records lack complete manufacturing and control instructions, sampling and testing procedures and specifications.

Auto-Chlor System LLC · Hapeville, Georgia · Drugs · 2024-06-18

Master production and control records lack complete manufacturing and control instructions.

Warner Graham LLLP · Cockeysville, Maryland · Drugs · 2024-05-21

Master production and control records lack complete manufacturing and control instructions, sampling and testing procedures, specifications, special notations and precautions to be followed.

Hybrid Pharma LLC · Deerfield Beach, Florida · Drugs · 2023-11-09

Master production and control records lack complete manufacturing and control instructions and sampling and testing procedures.

Higley Industries, Inc. · Dyersville, Iowa · Drugs · 2023-09-21

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharmaceutical quality systemPharma industry

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →